TRANSCRIPT

Q3 2025 — Earnings call remarks

Q3 2025PDF · 15 pages196 KB
Earnings Conference Call
Third Quarter 2025 Remarks
Oct. 28, 2025
Moderator:
Good morning, and welcome to the UnitedHealth Group Third Quarter 2025
Earnings Conference Call. A question and answer session will follow
UnitedHealth Group’s prepared remarks. As a reminder, this call is being
recorded.
Here is some important introductory information. This call contains “forward-
looking” statements under U.S. federal securities laws. These statements are
subject to risks and uncertainties that could cause actual results to differ
materially from historical experience or present expectations. A description of
some of the risks and uncertainties can be found in the reports that we file with
the Securities and Exchange Commission, including the cautionary statements
included in our current and periodic filings.
This call will also reference non-GAAP amounts. A reconciliation of the non-
GAAP to GAAP amounts is available on the “Financial & Earnings Reports”
section of the Company’s Investor Relations page at
www.unitedhealthgroup.com.
Information presented on this call is contained in the Earnings Release we issued
this morning and in our Form 8-K dated October 28, 2025, which may be
accessed from the Investor Relations page of the Company’s website. I will now
turn the conference over to the chairman and chief executive officer of
UnitedHealth Group, Stephen Hemsley.
Stephen Hemsley
Good morning, thank you for joining us today.
Our enterprise continues to advance on the improvement paths first discussed
with you in July. We have been introducing new leaders, strengthening
underperforming businesses, identifying both opportunities and inefficiencies
and, importantly, recommitting to the mission and culture of this company. We
are getting at the core of the underperformance issues with fresh perspectives,

-- 1 of 15 --

intent on positioning our organization as a positive and innovative leader helping
to advance the next era of health care.
A keen sense of urgency in this effort is consistent throughout the enterprise, at
the same time recognizing the pace of progress varies across our businesses
depending upon their challenges and opportunities. Some efforts will require
more time and investment. Others will show more immediate progress.
Repricing within UnitedHealthcare is on track to drive solid operating earnings
growth from margin improvement within that business in 2026. In our less mature
businesses, such as Optum Health and Optum Insight, our efforts to improve
operations and make needed investments will show more measured progress in
2026 and will take more time to fully bear fruit. As Patrick Conway will discuss,
our belief in the need for and impact of value-based care remains intact, as is our
confidence in returning to expected performance standards. And throughout the
company we will ensure we are focused on activities that align with our long-term
future and be very disciplined about moving on from those that do not. We are
committed to returning to the consistent enterprise-wide performance levels you
should expect of us.
Within Optum Health, the team has taken concrete steps that will refocus the
business back to its original mission – actions that will narrow networks with
more emphasis on appropriately aligned physicians, geographies, the right
clinical services, and the right benefit offerings for the members we serve.
We are also keeping sharp focus on the continued competitiveness of
UnitedHealthcare, as evidenced by our recent Medicare Stars scores showing
improvement year over year. And that work remains intense, now for payment
year 2028 Stars performance.
As we look ahead to the next few years, we will consistently emphasize the
fundamental execution discipline that has long been a key trait of this company –
and I am gratified to see the quick and enthusiastic response to this emphasis
from our leadership team. External challenges will remain, including continued

-- 2 of 15 --

headwinds in 2026 from the third year of nearly $50 billion in industry-wide
Medicare cuts by the previous Administration, as well as Medicaid funding and
program pressures. Even so, I am confident we will return to solid earnings
growth next year given the operational rigor and more prudent pricing.
While we are still finalizing 2026 plans and intend to share full guidance with you
in January, current analyst consensus captures a likely stepping off point for next
year. We intend to balance our earnings growth ambitions in 2026 with
investments and actions that will drive higher and sustainable, double-digit
growth beginning in 2027 and advancing from there.
That is the perspective we are keeping front of mind. Our longer-term outlook will
be refreshed as we continue to execute over the next year. As we have been
doing these last few months, we will continue to engage actively with both
investors and the broader stakeholder community and plan to convene our
investor conference in the back half of 2026.
This morning, Tim Noel and Patrick Conway will provide details on the progress
of UnitedHealthcare and Optum, respectively. Our Chief Financial Officer, Wayne
DeVeydt, will review third quarter results. I’m pleased to welcome Wayne to our
leadership team. He has the right experience, values, and expertise to help guide
UnitedHealth Group at this moment in our development, and he is off to a fast
start. With that, Tim, do you want to take it?
Tim Noel
Thanks, Steve.
For the current year, overall UnitedHealthcare performance remains in line with
the expectations we offered in the second quarter. Medical cost trends remain
historically high but consistent with our second quarter guidance, and we expect
that to continue throughout the remainder of 2025.

-- 3 of 15 --

Turning to our efforts for 2026 – a vital element has been our pricing. Since our
last update with you, we’ve repriced the vast majority of our UHC risk businesses
— including Medicare Advantage and, to varying degrees, our commercial fully
insured and residual ACA offerings. Trend experience through the third quarter
continues to validate the actuarial forecasts underpinning our 2026 pricing
actions.
Taken together, these actions position each of our businesses on a clear path
toward margin growth in 2026, with the exception of Medicaid, which I will
discuss in a moment.
Our Medicare business continues to perform in line with the expectations we
shared last quarter. That’s true for care activity and medical cost trends and,
importantly, for the mix of clinical activity and utilization — across physician,
outpatient, and inpatient. We forecast a full-year 2025 trend of approximately
7.5% in Medicare Advantage, consistent with our previous expectations. As we
shared with you last quarter, trend remains elevated across Medicare overall,
with our Med Supp offerings still seeing medical cost trends in excess of 11%.
In Individual Medicare Advantage, we continue to believe an expected 10%
medical cost trend for 2026 has us positioned appropriately. This trend
assumption reflects a continuation of the elevated care activity levels observed in
2025, known impacts from fee schedule changes, and continued expansion of
aggressive provider coding and billing practices.
We have taken a similarly prudent view across all our Medicare product offerings
for 2026 – including Medicare Supplement, Group MA, and standalone Part D.
For Medicare Advantage, we’re now about two weeks into the Annual Enrollment
Period and early results are in line with our strategic positioning for 2026.
Our plan for next year reflects a conservative path focused on margin growth. We
made significant adjustments to benefits and executed targeted plan exits and

-- 4 of 15 --

network reductions to offset elevated medical trends and government funding
decreases.
As a result of our plan actions, as well as competitive market dynamics, we
expect membership contraction of approximately one million members in total
Medicare Advantage, including individual and group markets.
We expect these actions will drive margin improvement in 2026 with potential for
further advancements in 2027 that will position us to reach the upper half of our
2% to 4% targeted margin range — all of which is supported by strong Stars
results. As Steve mentioned earlier, we already have shifted focus to the next
Stars performance period, including incremental investments made in the fourth
quarter.
Turning to Commercial, we are focused on pricing and cost management efforts
to support 2026 margin recovery. At this point, approximately 60% of our group
commercial insured offerings have been priced for next year.
Our commercial pricing reflects the elevated cost levels we’ve seen this year,
which we expect to persist in 2026. While we expect our group fully-insured
business to contract in line with the broader market, we continue to see strong
traction for our self-funded offerings. We expect the vast majority of our employer
insurance businesses to be repriced for 2026 and to return to our normal margin
range in 2027.
Moving to ACA markets, we have submitted rate filings in nearly all of the 30
states where we participate that reflect 2025 morbidity and experience. These
include average rate increases of over 25%. Where we are unable to reach
agreement on sustainable rates, we are enacting targeted service area
reductions. We believe these actions will establish a sustainable premium base
— while likely reducing our ACA enrollment by approximately two-thirds.
These actions should drive margin improvement in our Employer and Individual
segment in 2026 — though still below our targeted 7–9% range.

-- 5 of 15 --

In Medicaid, the path to recovery will be more challenging. States have not
funded in line with actual cost trends, so funding levels are not sufficient to cover
the health needs of state enrollees. While we’re making steady progress in
bridging this gap with states, the mismatch between rate adequacy and member
acuity will likely extend through 2026.
To date, we have received 2026 draft rates on almost half of our contracts which
have a January 1 rate cycle, and we continue to advocate for rate updates to
better reflect our ongoing experience with elevated trends. Our team is focused
on addressing drivers unique to these markets, especially behavioral health, and
will continue to push for appropriate funds. As I said last quarter, wherever states
support responsible funding for Medicaid, we remain committed to serving people
through that program and view this as integral to our mission.
As we indicated in July, we anticipate Medicaid margins will be breakeven for
2025. As we look to 2026, we expect margins to decline further if existing cost
trends continue and the current rate environment does not change.
Looking at UnitedHealthcare overall, the underlying business continues to
perform well in serving consumers, plans, and program sponsors. To give you
some examples of how we are enhancing the experience for these cohorts:
• Nearly 85% of member inquiries are served digitally. When members
call us, 90% of calls are answered within 30 seconds and 95% of
members’ questions are resolved in the first interaction.
• Some 95% of our claims are automatically processed immediately.
We’re delivering more value, ease, simplicity and guidance throughout the UHC
member experience. We’re also aggressively scaling AI and machine learning
capabilities to enhance these experiences and optimize core performance.
While 2025 remains a transition year, the pressure we experienced is largely a
result of mispricing and suboptimal market positioning. We remain humbled by

-- 6 of 15 --

the challenges of this environment and the lessons we have had to learn once
again, but confident that we are on solid footing to recapture our performance
potential.
With that, I’ll turn it over to Patrick Conway, CEO of Optum.
Patrick Conway
Thanks Tim.
I will spend the majority of my time today updating you on our efforts to restore
Optum Health to its original intent around value based care – which experience
continues to show us is the optimal model to deliver the right care, at the right
time, in the right setting, for the best outcomes, at the lowest cost to the people
we serve – particularly in light of current cost trends and the market dominance
of the large health systems.
Over the last few years, through a period of rapid expansion, Optum Health’s
strategy around value-based care strayed from the initial intent of the model.
Three critical issues emerged: first, the provider network grew too large; second,
the rapid pace of expansion and slower pace of integration resulted in operating
inconsistencies, exacerbated by relying too much on affiliated physicians who are
less aligned with core VBC policies. And, lastly, Optum Health was accepting risk
in products and services less suited for a clinically-oriented, value-based model.
Understanding these issues has helped us better pursue the steps needed to get
back to the original intent of Optum Health and value-based care.
Over the past six months, we have made significant leadership changes to better
drive an integrated VBC provider model. Under the leadership of Krista Nelson,
our Chief Operating Officer, we are focusing our efforts on three key, connected
areas to drive better performance: first, returning to the original intended clinical
framework that best supports VBC; second, moving towards narrower, more
integrated and dedicated value-based care provider model and network; and
third, focusing on the appropriate managed benefit product and patient base.

-- 7 of 15 --

Within this framework, our team has made solid progress, especially in bringing
greater discipline to how we approach risk arrangements, which will benefit the
business in 2026. This includes partnering with payers on benefit adjustments
and appropriate rates to match the risk and mix of the populations we serve.
At this point we are close to completion in over 90% of our value-based payer
contracts for next year and are on track to reach our goal of offsetting
approximately half of the 2026 V28 headwind through payer contracting. We are
also pursuing market and product exits, including from lower-performing PPO
contracts. As indicated last quarter, we have finalized exits for 200,000 lives in
2026, the majority of which are PPO. While still early in the Medicare annual
enrollment period, we expect total Optum Health value-based care membership
to shrink by approximately 10% in 2026 before returning to growth in 2027.
We also continue to intentionally shape our care provider network to prioritize
high-performing partners who demonstrate strong patient engagement and
consistently positive outcomes. We are moving to employed or contractually
dedicated physicians wherever possible. We are separating from providers who
are less aligned with the VBC model. The targeted network actions we’ve taken
over the last 60 days will result in fewer providers in our networks starting in
2026.
Within our markets and their related networks, we are working to more fully
integrate our clinical practices to ensure greater performance consistency. The
team is refining our portfolio and accelerating a consistent national operating
model for regionally led, high-performing Optum Health practices that reduces
fixed costs, drives purchasing economies, aligns technology and, most
importantly, ensures continued high quality care. These actions increase our
confidence in our ability to meet our V28 cost reduction targets in 2026 and
strengthen our operating foundations for the long term.
Lastly, our engagements and clinical work at Optum continue to track with our
expectations for meaningfully reducing medical cost trends – engaging with over

-- 8 of 15 --

85% of our high risk members in 2025 – which accounts for the remaining V28
pressure offsets in 2026.
Bottom line: Getting back to the basics of our VBC model will be good for the
people we serve and for our business. As a point of reference, our 2026 CMS
Star Rating projections show 80% of Optum at Home members in 4+ star plans
and nearly 100% of our ISNP members in 4+ Star plans. Evidence of our quality
of care is underscored by a strong NPS of 90 at our highest-performing facilities.
For the third quarter, Optum Health performance was in line with our
expectations, reflecting the natural seasonality in our business and the pull-
forward of some investments. Within this, we expect to end 2025 with margins of
just under 3%, which includes value-based care margins under 1%. We expect
margin improvement across all of Optum Health in 2026, even in the face of the
third year of the Medicare funding cuts. We believe these efforts will drive further
acceleration in 2027 towards our long-term margin targets of 6-8%.
Turning to Optum Health’s fee-based care services. As we discussed last time,
these were not performing to their potential. We are adopting more consistent
and rigorous processes to better manage these practices for growth and
appropriate profitability.
We are seeing early results in our East region, which serves nearly 5 million
patients, where we have generated a 3% per-visit productivity increase quarter-
over-quarter, driven by targeted improvements in scheduling, workflow efficiency
and patient acquisition. We have similar undertakings in motion in our south and
west regions.
As for Optum Insight, we continue to perform solidly but not at the level of the
potential for these services. Under the leadership of Sandeep Dadlani, we now
see the alignment of our end-to-end technology and AI innovation efforts coming
into formation. We will make the investments needed to accelerate the
advancement of this distinctive platform that serves the expanse of the health

-- 9 of 15 --

system. We are confident in our plan will ignite topline revenue and operating
earnings in line with our long-term growth targets.
At Optum Rx…we continue to perform well, with double-digit revenue growth in
our pharmacies and a strong selling season for our pharmacy offerings. Our
products are resonating in the market, with stronger customer retention and new
customer growth. At this stage, we expect new membership growth in 2026 will
be more than offset by expected membership attrition from the UnitedHealthcare
business. Importantly, our team remains disciplined around pricing, transparency,
and quality outcomes for our customers at a time when the pharmaceutical
industry continues to drive costs ever higher.
Today, we offer full rebate pass-through arrangements to all of our customers,
with nearly 85% of them participating. We were the first in our industry to
announce this arrangement back in the beginning of this year, and we expect
95% of our customers will be in these arrangements in 2027, with the remainder
in full rebate pass through by 2028. And we have increased payments on
branded drugs to over 14,000 independent retail pharmacies as part of our
commitment to a balanced pricing approach.
Thanks for your time today. I’ll now turn it over to Wayne DeVeydt.
Wayne DeVeydt
Good morning, everyone. I'd like to begin by expressing my sincere appreciation
to Steve, Tim, Patrick, and all of my colleagues at UnitedHealth Group for the
warm welcome. It's truly an honor to be part of this team and to contribute to our
shared mission.
Today, I’d like to cover three important topics. First, I’ll provide an overview of our
quarterly performance and how it informs our outlook for the rest of the year. I will
then discuss our capital and liquidity framework as we look ahead to 2026,
particularly in terms of resuming share buybacks and strategic acquisition
activities. And finally, I’ll offer some insights into our expectations for 2026.

-- 10 of 15 --

Moving to the quarter:
Today we reported adjusted earnings per share of two dollars and ninety-two
cents, which was slightly ahead of our expectations. These results reflect steady
execution while we work through our longer-term improvement plans. We’ve
balanced immediate performance with strategic investments that will support our
future growth and natural diversification.
Some details for the quarter:
• We delivered revenues of over $113 billion, reflecting 12% year-over-year
growth, driven by domestic membership expansion of over 780,000 lives
year to date. We ended the third quarter with total domestic membership
of more than 50 million.
• Our medical care ratio of 89.9% in the quarter compares to 85.2% in the
same quarter last year, with the full year trending toward the lower end of
the projections we offered last quarter. As Tim stated, medical cost trends,
while historically high, remain consistent with our outlook for 2025 and
align with our pricing actions for 2026.
• The Operating Cost Ratio of 13.5% in the quarter reflects larger
investments in technology and people than originally contemplated when
guidance was set in 2Q. Specifically, we invested more than $450 million
in broad-based employee incentives and in contributions to the
UnitedHealth Foundation, both critically important for strengthening our
relationships with our workforce and with local communities and the health
system at large. And investments were proportionately greater in Optum
Health and Optum Insight.
• Finally, our earnings were supported by strong cash flows of 2.3 times net
income and an overall increase in days claims payable of 1.7 days
sequentially.
Turning to our Capital and Liquidity Framework…

-- 11 of 15 --

As previously communicated, we have paused our strategic acquisitions and
share buy-back while we dedicate our cash to returning to a long-term debt-to-
capital ratio around 40% and interest coverage ratios in-line with historical levels.
In the third quarter, our debt to capital ratio remained stable at 44.1%, reflecting
continued actions to improve cash efficiency, offset by the completion of the
Amedisys transaction late in the third quarter, which represented a net cash
disbursement of $3.4 billion. We expect our debt-to-capital ratio to trend closer to
40% in the second half of 2026. Accordingly, while we have not finalized plans
for 2026, we anticipate we may be in a position to reinstate our historical capital
deployment practices later in the year.
Finally, we generated operating cash flow from operations of $5.9 billion. We still
expect to close this year with $16 billion in operating cash flow, or 1.1x net
income.
Looking ahead to 2026…
As Steve mentioned, we will provide formal guidance with our fourth quarter
results in January. We are comfortable with current consensus, and within that
we are making the requisite investments needed to accelerate our returns in
2026 and to position our company for meaningfully stronger growth in 2027 and
beyond.
We are optimistic in our ability to execute on our 2026 plans, but there are
remaining headwinds we will have to overcome. Items to keep in mind include:
• We are entering the final year of V28, which represents a more than $6
billion headwind to the overall enterprise. As you heard from Tim and
Patrick, we’ve taken numerous actions around benefit design, cost control
and member engagement to substantially offset this impact.

-- 12 of 15 --

• Further investment in Optum Health and Optum Insight is needed and we
are accelerating some of those investments as noted in our third quarter
results.
• We are also accelerating our pace of AI applications to fundamentally
advance a vast spectrum of processes and capabilities we expect will
structurally improve our enterprise performance.
• Our effective tax rate is expected to return to a more normalized level in
2026 as compared to 2025.
• And finally, investment income should continue to move lower as interest
rates decline.
From a tailwind perspective:
• Our repricing efforts will be a catalyst for earnings growth as we begin
returning to our long-term target margins, with particularly solid year-over-
year results expected in our Commercial and Medicare businesses.
• We also expect stability and a measured return to growth in our Optum
entities, with aspects of that growth being reinvested in the
business…specifically, Optum Health and Optum Insight. These
investments may slow 2026 growth but should accelerate growth in 2027
more in-line with historical expectations.
• We will be paying down debt and identifying opportunities to further
reduce our interest expense as a result of the declining rate environment.
• Finally, we are taking an aggressive step on affordability initiatives that
should improve overall medical trend relative to our pricing.

-- 13 of 15 --

While we have a number of moving parts to manage for the remainder of this
year, we also have concrete plans to execute on all the items we discussed this
morning that will position us for the type of growth you’ve come to expect from
UnitedHealth Group.
Thanks for your time this morning. I’ll now turn it back to Steve.
Stephen Hemsley
Thanks, Wayne.
As I hope you heard clearly, this team and our 400,000 colleagues are focused
on delivering on all fronts…for the people we are privileged to serve, and for our
shareholders.
As I said in the outset, we are being very disciplined. This plays out day to day as
this management team recognizes the need to manage our costs both in the
short term as well as structurally.
And through another lens, throughout the quarter, we have continued to evaluate
the company’s businesses with fresh perspectives and with continued confidence
in our progress and our overall direction. We expect to complete that assessment
in the fourth quarter as we position for 2026 and the years ahead. A few themes
emerge from these efforts:
• We are dedicating our energies to serving U.S. health care needs and will
be reducing our footprint in international markets that do not support these
needs.
• We will be finalizing our initiatives for recovery of the remaining
outstanding loan balances from the care provider support programs
associated with the 2024 Change Health cyber attack.

-- 14 of 15 --

• For Optum Health, we are consolidating locations and completing plans
addressing the geographic markets in which we will serve patients, all
intended to operationally advance and scale the leading value-based
clinical care business of Optum Health.
• And, we are realigning Optum Financial Services within our Optum Insight
services platform.
While we have not yet finalized these plans, many of these actions are underway
and we believe they will improve both our focus and long-term performance. We
are in the process of quantifying the accounting, tax and cash implications of our
plans. At this stage, our preliminary work would imply a non-GAAP, substantially
non-cash, low single digit billion dollar charge. We will provide further details in
our fourth quarter call as we conclude these efforts.
Simply put, we will end 2025 well-positioned for a return to solid growth in 2026,
acceleration in 2027, and a clear focus on our longstanding mission and strategy.
An important reason for my confidence in our outlook is the way I see our people
embracing a renewed focus on the mission, culture and values of our company.
How we go about things in the sensitive area of health care is as essential as
what we do, and we are bringing new energy to that imperative each day.

-- 15 of 15 --